Advia 2120 hematology analyzer

Whole blood samples (5 ml) were collected using venipuncture. 3 ml was added to a gel and clot activator tube for separating sera. The remaining 2 ml was placed into an EDTA tube for complete blood cell count including WBCs and lymphocytes. Oropharyngeal and nasopharyngeal swabs were collected for SARS-CoV-2 diagnosis and viral clearance was evaluated by real-time PCR. A questionnaire was provided to all participants asking about their possible exposure to SARS-CoV-2 infection. Complete blood count (CBC) was performed using an Advia 2120 hematology analyzer (Siemens Healthcare).

Treatment for anemia was provided with a target Hb level of 10–12 g/dL according to the guidelines of the Japanese Society of Dialysis Therapy. The dose of DA was adjusted accordingly. Rox administration was continued at the initial dose according to the package insert, and no iron supplement or iron-containing phosphate adsorbent was used during the observation period.
Rox administration was started 1 week after the last dose of DA. Rox was administered 3 times weekly at each dialysis session. The administered dose was 70 mg in patients who had received DA at doses of < 20 μg/week and 100 mg in those who had received DA at doses of ≥ 20 μg/week, following the directions on the package insert.
Blood samples were collected at the start of HD on the first day of Rox administration (Day 0) and Day 28 to measure mature erythrocytes, reticulocyte indices (Ret count, CHr), iron-related factors, hepcidin levels, and EPO concentration. TSAT was calculated as serum iron concentration divided by total iron-binding capacity multiplied by 100. Erythrocyte lineage cells were counted using an ADVIA2120 hematology analyzer (Siemens Healthcare Diagnostics, Tarrytown, NY), EPO concentration was measured by chemiluminescent enzyme immunoassay, and hepcidin levels were quantitatively measured by liquid chromatography coupled with tandem mass spectrometry [18 (link)].